Opinion & Thought Leadership · Central Africa

Congo's Ebola Emergency Exposes the Gap Between Pledges and Protection

By: Nia Mbala

As eastern DR Congo's Ebola outbreak nears 5,700 deaths and spreads into nearly 100 schools, humanitarian groups warn that funding announced on paper is not reaching clinics. The crisis reveals how conflict, political distraction and donor accounting failures compound one another, with lessons for the whole region.

Six months into the deadliest Ebola outbreak in the Democratic Republic of Congo's history, the most urgent story emerging from Central Africa this week is not a single announcement but a pattern: the widening distance between what is promised to fight the epidemic and what actually reaches the people dying from it. With 11,680 confirmed cases and 5,700 deaths recorded, and nearly 100 schools now reporting infections among students, the outbreak has moved from a public health emergency to a test of whether the international and regional response architecture can function under conflict conditions. That test, on the evidence available, is being failed in important respects.

The facts are stark enough on their own. Médecins Sans Frontières has called for wider access to the Ervebo vaccine, which remains confined to a clinical trial even as the World Health Organization reports 400 to 500 new cases weekly. Two additional vaccine candidates, ChAdOx1 and mRNA-1469, are due to join that trial before December, with results not expected before early 2027 in the most optimistic scenario, according to the Coalition for Epidemic Preparedness Innovations. Meanwhile, Ituri and North Kivu provinces have recorded dozens of student deaths since schools reopened in September, a detail that should alarm any reader concerned with the generational cost of prolonged crises. The Norwegian Refugee Council, for its part, has pointed to a funding paradox: Africa CDC reports more than $900 million disbursed, yet humanitarian organisations on the ground say they have received only about a third of that figure, with strikes, underpaid health workers and under-equipped treatment sites still the norm in some areas.

It is worth being precise about what is established fact and what remains contested. The scale of the outbreak, the vaccine trial timeline, and the discrepancy between announced and received funding are documented by multiple organisations with direct operational knowledge. What is less clear is where the shortfall originates — whether in slow disbursement mechanisms, diversion, administrative bottlenecks, or simply the difficulty of auditing aid flows in a warzone. Dr De-Joseph Kakisingi's question — whether the money has actually been disbursed at all — deserves to be treated as a serious open question rather than an accusation to be assumed true. Readers should resist the temptation, visible in some commentary, to collapse this uncertainty into either a simple narrative of donor generosity or one of donor failure. Both pledges and genuine delivery difficulties appear to be real.

What can be argued with more confidence is that the outbreak's persistence is inseparable from the security crisis convulsing eastern Congo. Health workers and surveillance teams have been attacked in communities that distrust outside intervention, and fighting between the Congolese army and Front for the Refoundation of the Nation-allied forces has forced MSF to relocate hospital services in Bunyakiri, disrupting care for a population of nearly 300,000 already facing cholera and malaria. This is the structural truth that too much of the international conversation about vaccines and funding tends to obscure: no clinical trial design, however well resourced, can outrun a conflict that keeps displacing the very populations epidemiologists need to reach and keeps making health infrastructure a casualty of war. The WHO's own acknowledgment that delays in paying frontline workers have created tension and slowed the response only reinforces how administrative failure and insecurity reinforce each other.

There is a legitimate counterargument that the response, despite its flaws, represents an extraordinary mobilisation by international standards — multiple vaccine candidates advancing in parallel, sustained donor pledges despite global aid cuts, and continued operational presence by agencies in deeply dangerous terrain. This is true, and it would be unfair to suggest that the effort has been negligible. But extraordinary effort measured against extraordinary need is not the same as sufficient effort, and the gap between the two is precisely where thousands of additional deaths, including among schoolchildren, are occurring.

For African readers and policymakers, the practical implications are threefold. First, the case for strengthening Africa CDC's own capacity to track disbursement transparently — publishing where funds actually land, not merely what has been pledged — is now overwhelming; donor trust and African sovereignty over health data both depend on it. Second, any regional health security strategy must treat conflict resolution as a prerequisite for epidemic control, not a parallel track; the Doha and Washington peace processes and the Ebola response cannot be managed as separate files when they are, in the field, the same crisis. Third, the involvement of community and religious leaders, repeatedly cited by vaccine officials as essential to enrollment and trust, should be treated not as a public relations afterthought but as core infrastructure deserving direct funding.

The deeper lesson for the region is that epidemics in conflict zones do not merely test medical science; they test governance, accountability and the credibility of international partnership. DR Congo's Ebola outbreak will eventually be contained, as previous ones were. Whether it is contained before tens of thousands more die, and whether the funding and security failures exposed along the way are honestly addressed, will say a great deal about whether Central Africa's partners — domestic and foreign alike — have learned anything from six months of documented, preventable delay.

Reporting context: - MSF Calls for Wider Access to Ervebo Vaccine as DR Congo Ebola Toll Reaches 5,700: /article/msf-calls-for-wider-access-to-ervebo-vaccine-as-dr-congo-ebola-toll--5c3cbafdb0 - Nearly 100 Schools in Eastern DR Congo Report Ebola Cases, With Dozens of Students Dead: /article/nearly-100-schools-in-eastern-dr-congo-report-ebola-cases-with-dozen-0ec3d704e2 - Ebola Vaccine Trials in DR Congo Could Yield Results Early Next Year if Insecurity Is Overcome: /article/ebola-vaccine-trials-in-dr-congo-could-yield-results-early-next-year-facbe8f142 - NRC Urges More Inclusive Ebola Response in DR Congo as Funding Gap Questions Persist: /article/nrc-urges-more-inclusive-ebola-response-in-dr-congo-as-funding-gap-q-6cbe875996 - Fighting Continues in Eastern DR Congo as Peace Tracks Yield Little Change on the Ground: /article/fighting-continues-in-eastern-dr-congo-as-peace-tracks-yield-little--a6f2f24152 - MSF Moves Bunyakiri Hospital Activities After Fighting in DR Congo's South Kivu: /article/msf-moves-bunyakiri-hospital-activities-after-fighting-in-dr-congo-s-de58246a15

More reporting from Voice of Africans